Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTONE versus PENECORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTONE versus PENECORT.
HYDROCORTONE vs PENECORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid that binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
PENECORT is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammation, immune responses, and adrenal function.
100-500 mg intravenously every 2-6 hours for initial management of adrenal insufficiency; oral maintenance: 20-30 mg daily in divided doses (e.g., 10 mg morning, 5 mg afternoon).
2.5-5 mg orally once daily; maximum 10 mg/day. Intramuscular: 20-40 mg every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 1.5–2.5 hours (plasma), but biological half-life (duration of HPA axis suppression) is 8–12 hours.
Terminal elimination half-life: 3-4 hours in adults; prolonged in hepatic impairment (up to 8 hours).
Renal (primarily as inactive metabolites; <5% unchanged) and biliary/fecal (minor).
Renal: 60-70% as metabolites, 5-10% unchanged; Biliary/fecal: 20-30% as metabolites.
Category C
Category C
Corticosteroid
Corticosteroid